Pneumococcal conjugate second or third-dose vaccines (PCVc) in Cuba
Cuba: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 99.0% in 2025. ◆ Volatile
Latest (2025)
99.0%
World rank
1st
of 194 countries
All-time high
99.0%
in 2025
All-time low
0.0%
in 2008
Years of data
18
2008–2025
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Cuba, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
In 2025, pneumococcal conjugate second or third-dose vaccines (pcvc) in Cuba stood at 99.0%. That is the highest value across all 18 years on record.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Cuba peaked at 99.0% in 2025 and was at its lowest, 0.0%, in 2008.
Cuba ranks 1st of 194 countries on this measure, in the top 10%.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Cuba, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 0.0% | — |
| 2017 | 0.0% | — |
| 2018 | 0.0% | — |
| 2019 | 0.0% | — |
| 2020 | 0.0% | — |
| 2021 | 0.0% | — |
| 2022 | 0.0% | — |
| 2023 | 0.0% | — |
| 2024 | 0.0% | — |
| 2025 | 99.0% | — |
Cuba compared with similar countries
- Cuba's 99.0% is above the median for upper middle income countries, which is 76.0%, 1.3× the median. (57 countries reporting)
- Cuba's 99.0% is above the median for Latin America & Caribbean, which is 82.5%, 1.2× the median. (32 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 0.0% | 0.0% | 0.0% | 10 |
| 2020s | 16.5% | 0.0% | 99.0% | 6 |
Countries ranked near Cuba
More health data for Cuba
- Un projection of annual infant deaths, annual growth rate -1.47 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -0.2059 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,696 deaths per 1,000 people (2090)
- Number of infants who die before age 1 67 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -2.62 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2020)
- Population ages 00-04, female, per capita 0.021 units per person (2025)
- Population ages 00-04, male, annual growth rate -2.64 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2020)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Cuba?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Cuba was 99.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Cuba?
- The highest recorded value was 99.0% in 2025.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Cuba?
- The lowest recorded value was 0.0% in 2008.
- How does Cuba rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Cuba ranks 1st out of 194 countries with data for 2025.
- Where does this Cuba data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).